Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXL3CD)

Drug Name
NVP-ADW742 Drug Info
Synonyms
NVP-ADW742; 475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Investigative [1]
Cross-matching ID
PubChem CID
9825149
CAS Number
CAS 475488-23-4
TTD Drug ID
DMXL3CD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Insulin-like growth factor I receptor (IGF1R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Teprotumumab DM4L59B Graves disease 5A02.0 Approved [3]
Mecasermin DM1O3BY Growth failure LD2F.1Y Approved [4]
Somatomedin-1 DMZ9FAO Hormone deficiency 5A61.1 Approved [5]
OSI-906 DMHKZLF Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
Rinfabate DML9FD4 Solid tumour/cancer 2A00-2F9Z Phase 2/3 [7]
MM-141 DM2RJ4D Pancreatic cancer 2C10 Phase 2 [8]
TT-100 DMZE6Y9 Non-small-cell lung cancer 2C25.Y Phase 2 [9]
AMG 479 DM0DRAZ Breast cancer 2C60-2C65 Phase 2 [10]
VPI-2690B DMUQZT4 Diabetic nephropathy GB61.Z Phase 2 [11]
AXL-1717 DMTQ1Y3 Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin-like growth factor I receptor (IGF1R) TTHRID2 IGF1R_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Vascular endothelial growth factor A, long form OTIM9MZ3 VEGFA_HUMAN Protein Interaction/Cellular Processes [2]

References

1 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
2 Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40. doi: 10.1158/1078-0432.CCR-05-1778.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
5 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
6 Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
7 Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
8 MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
9 BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
10 Clinical pipeline report, company report or official report of Amgen (2009).
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.